KUALA LUMPUR, July 20 (Bernama) -- Quantexa announced it has been recognised by Celent, a global research and advisory firm, for its standout technology in the 2023 xCelent Anti-Money Laundering (AML) Transaction Monitoring (TM) Report, an independent resource helping financial institutions select an AML vendor best suited to meet their needs.
Celent’s report profiled 17 AML TM systems available globally, including an overview of their functionality, customer base, technology, implementation, pricing and support, to help key financial institutions navigate the market.
“We continually strive to bring best-in-class solutions to our clients, helping them turn information into insight and insight into the ability to protect, optimise and grow their organisations.
“Having Celent recognise our solution for the depth of impact it delivers, as well as our teams’ breadth of knowledge, which is helping to aid in the forensic investigations of financial crime, is inspiring and rewarding,” said Quantexa Chief Product Officer, Dan Higgins.
According to a statement, Quantexa’s Decision Intelligence (DI) Platform and Financial Crime solutions credited for driving efficiencies via automation and enriching graph analytics and network analysis.
Customers rated Quantexa’s DI Platform and AML solutions strongly overall, with the speed of implementation and the flexibility of the data model receiving the highest scores for implementation experience and technology respectively.
They also appreciated the platform’s graph analytics and network/link analysis capabilities, while respondents noted the Quantexa team’s knowledge of their solution and relevant technology.
The global data and analytics software company’s platform gives leading banks, fintechs and regulators the ability to understand their data by connecting siloed systems to protect, optimise and grow.
By protecting and fighting against financial crime, Quantexa’s clients can become more resilient, visualise hidden risks at speed, and make more informed and trusted decisions about AML risk.
-- BERNAMA
No comments:
Post a Comment